This clinical trial focuses on patients with prostate cancer who have experienced a return of the disease after having their prostate surgically removed. The study is investigating the use of a special imaging technique called PET/CT with a solution known as 64CuCl2 to help identify patients who might benefit from additional treatment with radiation therapy on the area where the prostate used to be, known as the prostatic bed.
The purpose of the study is to evaluate how accurately the 64CuCl2 PET/CT scan can detect the return of prostate cancer in patients who have already had surgery and show signs of the disease coming back, as indicated by rising levels of a protein called PSA in their blood. This imaging method is being tested to see if it can find cancer that other traditional methods might miss. The study involves patients who have had a previous diagnosis of prostate cancer and have undergone surgery to remove the prostate, but now show signs of the disease returning.
Participants in the study will receive an injection of the 64CuCl2 solution, which is a type of imaging agent, and then undergo a PET/CT scan. The results of this scan will help doctors determine if there is a local recurrence of cancer in the prostatic bed. The study will also look at how the scan results might influence treatment decisions, such as whether to proceed with radiation therapy. The trial aims to provide valuable information on the effectiveness of this imaging technique in guiding treatment for patients with recurrent prostate cancer.
Italy 
